Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Arcus Biosciences, Inc. (RCUS) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/07/2023 10-Q Quarterly Report for the period ended June 30, 2023
08/07/2023 8-K Quarterly results
Docs: "Arcus Biosciences Reports Second-Quarter 2023 Financial Results and Provides a Pipeline Update • Presented data from the ongoing ARC-7 Phase 2 trial in non-small cell lung cancer at American Society of Clinical Oncology ; Fc-silent anti-TIGIT monoclonal antibody domvanalimab continued to demonstrate clinically meaningful improvements over anti-PD-1 monotherapy across all measures evaluated, including progression-free survival, overall response rate, and duration of response • Initiated the dose-expansion phase of the Phase 1b ARC-20 study of AB521, a potential best-in-class HIF-2a inhibitor, in clear-cell renal cell carcinoma patients at a dose of 100 mg daily; pharmacokinetic, pharmacodynamic and safety data, along with any preliminary signs of anti-tumor activity from the d..."
07/06/2023 SC 13D/A GILEAD SCIENCES, INC. reports a 35% stake in ARCUS BIOSCIENCES, INC.
06/16/2023 8-K Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits  Interac...
Docs: "ARCUS BIOSCIENCES, INC. AMENDED COMPENSATION PROGRAM FOR NON-EMPLOYEE DIRECTORS EFFECTIVE AS OF JUNE 15, 2023 A. Cash Compensation Annual cash retainers each paid quarterly, in arrears, as follows: 1. Retainer for each non-employee member of the Board: $45,000 2. Additional retainer for Lead Independent Director: $25,000 3. Additional retainer for Chair of Audit Committee: $20,000 4. Additional retainer for Chair of Compensation Committee: $15,000 5. Additional retainer for Chair of Nominating and Corporate Governance Committee: $10,000 6. Additional retainer for non-Chair members of Audit Committee: $10,000 7. Additional retainer for non-Chair members of Compensation Committee: $7,500 8. Additional retainer for non-Chair member of Nominating and Corporate Governance Committee: $5,000 B. E..."
06/07/2023 144 Form 144 - Report of proposed sale of securities:
05/15/2023 8-K Entry into a Material Definitive Agreement  Interactive Data
05/09/2023 10-Q Quarterly Report for the period ended March 31, 2023
05/09/2023 8-K Quarterly results
Docs: "Arcus Biosciences Reports First Quarter 2023 Financial Results and Provides a Pipeline Update • Four Phase 3 and two Phase 2 trials are now enrolling to evaluate domvanalimab-based combinations in lung and gastrointestinal cancers. • The third dose-escalation cohort of ARC-20 for AB521, a potential best-in-class HIF-2a inhibitor, is enrolling; the dose-expansion stage of ARC-20 and a Phase 2 combination study in clear-cell renal cell carcinoma patients are expected to begin in the third quarter. • Three new drug candidates are expected to advance into the clinic in 2023 and early 2024. • With $1.0 billion in cash, cash equivalents and marketable securities and funding into 2026, Arcus is well-positioned to advance its pipeline. HAYWARD, Calif. – – May 9, 2023 – ..."
04/25/2023 ARS Form ARS - Annual Report to Security Holders:
04/21/2023 DEFA14A Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material:
04/21/2023 DEF 14A Form DEF 14A - Other definitive proxy statements:
03/10/2023 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
02/28/2023 S-8 Form S-8 - Securities to be offered to employees in employee benefit plans:
02/28/2023 10-K Annual Report for the period ended December 31, 2022
02/28/2023 8-K Quarterly results
02/14/2023 SC 13G/A PFM Health Sciences, LP reports a 3.7% stake in Arcus Biosciences, Inc.
02/14/2023 SC 13G/A BIOTECHNOLOGY VALUE FUND L P reports a 3.2% stake in Arcus Biosciences, Inc.
02/09/2023 SC 13G VANGUARD GROUP INC reports a 6% stake in Arcus Biosciences Inc.
01/20/2023 SC 13G/A BlackRock Inc. reports a 13% stake in ARCUS BIOSCIENCES INC
12/19/2022 8-K Quarterly results
11/28/2022 8-K Quarterly results
11/02/2022 10-Q Quarterly Report for the period ended September 30, 2022
11/02/2022 8-K Quarterly results
10/17/2022 SC 13G PFM Health Sciences, LP reports a 5.5% stake in Arcus Biosciences, Inc.
10/11/2022 S-3ASR Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuers:
10/11/2022 8-K Entry into a Material Definitive Agreement, Financial Statements and Exhibits  Interactive Data
Docs: "Amendment No. 1 to Investor Rights Agreement",
"Amendment No. 1 to Investor Rights Agreement"
08/03/2022 10-Q Quarterly Report for the period ended June 30, 2022
08/03/2022 8-K Quarterly results
06/16/2022 8-K Quarterly results
06/07/2022 UPLOAD Form UPLOAD - SEC-generated letter:
06/03/2022 CORRESP Form CORRESP - Correspondence:
05/10/2022 UPLOAD Form UPLOAD - SEC-generated letter:
05/09/2022 10-Q Quarterly Report for the period ended March 31, 2022
05/09/2022 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy